Contact:
Dr. Dieter Nachtigall, COO
KetoLipix Therapeutics GmbH
Tel.: +49 151 58416175
d.nachtigall@ketolipix.com

Herrengraben 31
20459 Hamburg
Germany
www.ketolipix.com

PRESS RELEASE

KetoLipix Therapeutics announces the establishment of their drug discovery pipeline

- *New web appearance invites partners and interested parties to connect @* ***www.ketolipix.com***

Hamburg, 12. February 2025: KetoLipix Therapeutics today announced the establishment of their drug discovery pipeline based on a unique portfolio of proprietary ketone esters. The common principle of the therapeutic products to be developed will be the exogeneous creation of a ketogenic metabolic state. A wide range of clinical indications not sufficiently treated by existing therapeutic options such as certain forms of epilepsy will be amenable to this mechanistic approach.

Mark Tuchen, CEO of KetoLipix, commented: „I am delighted that we have successfully formed a team of highly experienced and distinguished scientists who already made great progress in selecting and profiling development candidates from our portfolio of compounds. Expertise in ketone ester chemistry, pharmaceutical development, clinical strategies and all other fields of drug discovery and development has been combined to establish a strategy for swiftly progressing towards testing our hypotheses in the clinic."

Tan Kean Hua, Chairman of the KetoLipix Board emphasized the significance of the KLX breakthrough technology: "KetoLipix Therapeutics has the great potential to establish novel and unconventional treatments for conditions with high medical need, thus creating new treatment options for patients. The company's chemical Core Shell Technology for designing ketone esters adds unprecedented opportunities in the exogeneous creation of ketosis."

KetoLipix particularly targets drug-resistant epilepsy in children as lead indication and plans to disclose further pipeline information in due course.

About KetoLipix Therapeutics

KetoLipix Therapeutics GmbH (KetoLipix) was founded in 2022 as a biotech start-up with the vision to treat diseases and improve patients' quality of life based on new therapeutic concepts. The company, a spin-off from IOI Oleo GmbH, Germany, and part of the IOI Group of companies, has established a pipeline of proprietary novel therapeutic active substances from a portfolio of several different classes of ketogenic compounds. It aims at addressing unmet medical needs in high-priority disease areas using the innovative chemical Core Shell Technology and high-quality GMP processes.